Haisco(SZ:002653) Shang Hai Zheng Quan Bao·2025-04-11 20:25Core Viewpoint - The company, Haizhi Pharmaceutical Group Co., Ltd., has reported its annual results, highlighting its commitment to innovation in drug development and marketing, with a focus on becoming a trusted international pharmaceutical enterprise. Company Overview - Haizhi is a specialized pharmaceutical company engaged in new drug research and development, manufacturing, and marketing, aiming to meet customer needs with innovative products [3][4]. Main Products and Applications - The company has over 40 products covering various fields, including anesthesia, neurology, and endocrinology. Key products include: - Rocuronium Injection: A new class of intravenous anesthetic approved in December 2020, noted for its safety and stability in various clinical settings [4][5]. - Pregabalin Capsules: Approved in May 2024 for treating diabetic peripheral neuropathic pain, filling a gap in the market [6]. - DPP-4 Inhibitor Tablets: Approved in June 2024, offering a long-acting option for type 2 diabetes management [7]. Business Model - The company employs a comprehensive business model focusing on innovation, academic marketing, and multi-channel sales to enhance commercial capabilities [10]. Financial Performance - The company reported a profit distribution plan based on a total of 1,119,917,970 shares, proposing a cash dividend of 1.35 yuan per 10 shares [2]. Meeting Resolutions - The board approved several key reports, including the annual financial report and internal control self-evaluation report, which reflect the company's adherence to legal and regulatory standards [19][24][75]. Fundraising and Utilization - The company raised 800 million yuan through a non-public offering in February 2023, with net proceeds of approximately 790.87 million yuan after expenses. As of December 31, 2024, 536.62 million yuan was utilized for projects, with 200 million yuan remaining for working capital [80][81]. Future Plans - The company plans to continue its focus on innovative drug development and expand its market presence through strategic marketing and product positioning [10][12].